Bucolome in prevention of hyperbilirubinaemia in preterm infants.
Open Access
- 1 July 1977
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 52 (7) , 549-550
- https://doi.org/10.1136/adc.52.7.549
Abstract
Fifty preterm babies were randomly assigned to a group given oral bucolome (30 mg/kg per day for 5 days) and a control group. Serum bilirubin levels of the treated infants from day 4 onwards were consistently lower than those of the control infants. 3 of the 25 control infants (but none of the 25 treated infants) had bilirubin levels greater than 18 mg/100 ml (308 mumol/l) and required exchange transfusion. No sedation or drowsiness was observed in the infants given bucolome, and though the drug caused some vomiting, weight gains were unaffected.This publication has 7 references indexed in Scilit:
- [Use of 5-butyl-1-cyclohexyl-2,4,6,-trioxoperidropyrimidine (BCP) in the prevention and therapy of neonatal hyperbilirubinemia. Comparative study with phenobarbital].1976
- [1-Cyclohexyl-5-butylbarbituric acid in the treatment of neonatal hyperbilirubinemia].1976
- FAMILIAL NONHEMOLYTIC JAUNDICE WITH LATE ONSET OF NEUROLOGICAL DAMAGEPediatrics, 1968
- Pharmacological studies of 5-n-butyl-1-cyclohexyl-2, 4, 6-trioxoperhydropyrimidine (BCP), a new anti-inflammatory agentFolia Pharmacologica Japonica, 1967
- THE DETERMINATION OF BILIRUBIN WITH THE PHOTOELECTRIC COLORIMETERJournal of Biological Chemistry, 1937